J&J’s Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care

New Brunswick, NJ January 21, 2025 Johnson & Johnson (NYSE:JNJ) has finally got its breakthrough depression treatment, Spravato (esketamine), approved by the U.S. FDA (Food and Drug Administration) as thefirst and only standalone monotherapy for TRD (treatment-resistant depression).

Spravato was already available in the market before today’s FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD. Despite the highprice, the sales of Spravato increase 60% brought in $780 million in sales in the first nine months of 2024, compared to the same quarter in 2023.

Spravato is a standalone treatment that is more accessible to patients with oral antidepressant intolerant, it’s known for fast-acting and more effective treatments than traditional antidepressants. With FDA approval, J&J’s Spravato is poised to capture a larger share of the mental health treatment market and contribute to more than $1 billion in revenue for J&J in the coming year.

Revolutionizing Depression Treatment

Spravato is a nasal spray that regulates mood by targeting the NMDA receptor in the brain. The action mechanism allows quicker relief from depressive symptoms just in hours while other standard antidepressants could take weeks before showing progress.

Investor Sentiment and Stock Performance

J&J shares experienced a modest gain of 0.97% following the announcement. As the mental health crisis and awareness continues to grow globally, Spravato’s approval may help it to become a leader in the depression treatment.

You can make more informed investment decision by visiting GuruFocus now and deep dive into Johnson and Johnson’s performance with charts, breakdowns, 30 years of financials, insiders, guru insights, and more!

This article first appeared on GuruFocus.

This article was originally published by a finance.yahoo.com . Read the Original article here. .